Related Experiment Video
Updated: May 19, 2026

Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
Published on: November 1, 2024
Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells
Mika Kosaka1, Moo Rim Kang, Glen Yang
1Department of Urology and Helen-Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Abstract:
RNA activation (RNAa) is a mechanism of gene activation triggered by promoter-targeted small double-stranded RNA (dsRNA), also known as small activating RNA (saRNA). p21(WAF1/CIP1) (p21) is a putative tumor suppressor gene due to its role as a key negative regulator of the cell cycle and cell proliferation. It is frequently downregulated in cancer including hepatocellular carcinoma (HCC), but is rarely mutated or deleted, making it an ideal target for RNAa-based overexpression to restore its tumor suppressor function. In the present study, we investigated the antigrowth effects of p21 RNAa in HCC cells. Transfection of a p21 saRNA (dsP21-322) into HepG2 and Hep3B cells significantly induced the expression of p21 at both the mRNA and protein levels, and inhibited cell proliferation and survival. Further analysis of dsP21-322 transfected cells revealed that dsP21-322 arrested the cell cycle at the G(0)/G(1) phase in HepG2 cells but at G(2)/M phase in Hep3B cells which lack functional p53 and Rb genes, and induced both early and late stage apoptosis by activating caspase 3 in both cell lines. These results demonstrated that RNAa of p21 has in vitro antigrowth effects on HCC cells via impeding cell cycle progression and inducing apoptotic cell death. This study suggests that targeted activation of p21 by RNAa may be explored as a novel therapy for the treatment of HCC.
Insights
RNA activation (RNAa) therapy using small activating RNA (saRNA) to boost p21 expression inhibited hepatocellular carcinoma (HCC) cell growth. This approach suppressed proliferation and induced apoptosis, suggesting potential for HCC treatment.
Area of Science:
- Molecular Biology
- Gene Regulation
- Cancer Research
Background:
- RNA activation (RNAa) utilizes small activating RNA (saRNA) to upregulate gene expression.
- p21(WAF1/CIP1) (p21) is a tumor suppressor gene frequently downregulated in hepatocellular carcinoma (HCC).
- Restoring p21 function is a potential therapeutic strategy for HCC.
Purpose of the Study:
- To investigate the antigrowth effects of p21 RNAa in HCC cells.
- To evaluate the potential of p21 saRNA as a therapeutic agent for HCC.
Main Methods:
- Transfection of p21 saRNA (dsP21-322) into HepG2 and Hep3B HCC cell lines.
- Assessed p21 mRNA and protein levels post-transfection.
- Analyzed cell proliferation, cell cycle progression, and apoptosis induction.
Main Results:
- dsP21-322 significantly increased p21 expression in both mRNA and protein.
- p21 RNAa inhibited proliferation and survival of HCC cells.
- Cell cycle arrest occurred at G(0)/G(1) in HepG2 and G(2)/M in Hep3B cells.
- Apoptosis was induced via caspase 3 activation.
Conclusions:
- p21 RNAa demonstrates in vitro antigrowth effects on HCC cells.
- Mechanism involves cell cycle impediment and apoptosis induction.
- Targeted p21 activation via RNAa is a promising novel therapeutic strategy for HCC.
Related Concept Videos
Experimental RNAi
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Inhibition of Cdk Activity
Negative Regulator Molecules
Abnormal Proliferation
